Core Viewpoint - The company, Boji Pharmaceutical, emphasizes its competitive edge in traditional Chinese medicine (TCM) research and development services, focusing on providing comprehensive TCM R&D services and enhancing its capabilities in the field [1] Group 1: Business Focus - The company primarily offers TCM R&D services through its wholly-owned subsidiary, Xinglin TCM, which provides clinical, preclinical, and registration services for TCM [1] - The company’s controlling subsidiary, Henan Kangli, specializes in post-marketing re-evaluation services for TCM [1] Group 2: Research and Development Achievements - In the past two years, the company has successfully developed TCM Class 1.2 CRA (raw materials and formulations) and Class 1.1 Qingzhi ointment, both of which have received the "Drug Clinical Trial Approval Notice" [1] - Several innovative TCM self-research projects are currently in the preclinical development stage [1] Group 3: Future Strategy - The company plans to continue prioritizing TCM R&D services while supplementing its self-research efforts and aims to attract more TCM R&D talent to enhance its competitiveness in the TCM sector [1]